OBSEVA
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful bio... pharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.
OBSEVA
Industry:
Biotechnology Pharmaceutical Therapeutics Women's
Founded:
2012-01-01
Address:
Plan-les-ouates, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.obseva.com
Total Employee:
11+
Status:
Active
Contact:
+41 (0)22 552 3840
Total Funding:
228.37 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Board_member
Current Employees Featured
Brian O'Callaghan Chief Executive Officer and Member of The Board Of Directors @ ObsEva
Chief Executive Officer and Member of The Board Of Directors
2020-11-01
Brandi Howard CCO @ ObsEva
CCO
2022-05-01
Jacky Vonderscher Independent Director @ ObsEva
Independent Director
2013-10-01
Fabien de Ladonchamps Chief Administrative Officer & VP Corporate Affairs & Finance @ ObsEva
Chief Administrative Officer & VP Corporate Affairs & Finance
2019-01-01
Tim Adams Chief Financial Officer @ ObsEva
Chief Financial Officer
2017-01-01
Jean-Pierre Gotteland Chief Scientific Officer and Head of R&D @ ObsEva
Chief Scientific Officer and Head of R&D
Ernest Loumaye Co-Founder & CEO @ ObsEva
Co-Founder & CEO
2012-11-01
André Chollet Co-Founder & CSO @ ObsEva
Co-Founder & CSO
Luigi Marro Chief Transformation Officer @ ObsEva
Chief Transformation Officer
2021-09-01
Elizabeth Garner MD MPH Chief Medical Officer @ ObsEva
Chief Medical Officer
2019-07-01
Founder
Stock Details
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - ObsEva
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - ObsEva
Omega Funds
Omega Funds investment in Post-IPO Equity - ObsEva
Aisling Capital
Aisling Capital investment in Post-IPO Equity - ObsEva
Venrock
Venrock investment in Post-IPO Equity - ObsEva
New Leaf Venture Partners
New Leaf Venture Partners investment in Post-IPO Equity - ObsEva
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - ObsEva
Sofinnova Investments
Sofinnova Investments investment in Post-IPO Equity - ObsEva
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - ObsEva
New Enterprise Associates
New Enterprise Associates investment in Series B - ObsEva
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-02 | ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer |
| 2021-09-30 | ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer |
| 2020-04-06 | ObsEva SA Announces New Interim Chief Financial Officer |
Official Site Inspections
http://www.obseva.com Semrush global rank: 3.87 M Semrush visits lastest month: 3.35 K
Unable to get host informations!!!
More informations about "ObsEva"
ObsEva - Crunchbase Company Profile & Funding
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is …See details»
ObsEva Company Profile 2025: Stock Performance
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious …See details»
ObsEva SA (OBSEF) Company Profile & Facts - Yahoo Finance
See the company profile for ObsEva SA (OBSEF) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
ObsEva Announces Wind-Down of Operations and Notifies SIX …
ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused …See details»
ObsEva
ObsEva is a biopharmaceutical company focused on advancing reproductive health and pregnancy therapeutics for women worldwide.See details»
ObsEva SA - LinkedIn
ObsEva SA | 3,182 followers on LinkedIn. ObsEva. Nature meets Nurture | Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a clinical-stage …See details»
ObsEva - Funding, Financials, Valuation & Investors - Crunchbase
ObsEva is registered under the ticker NASDAQ:OBSV . Their stock opened with $15.00 in its Jan 26, 2017 IPO. Stock Symbol NASDAQ:OBSV ; Valuation at IPO $96.8M; Money Raised at …See details»
ObsEva - AnnualReports.com
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's …See details»
ObsEva Company Profile - Office Locations, Competitors, Revenue …
ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in …See details»
ObsEva - VentureRadar
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and …See details»
ObsEva Announces Strategic Reorganization to Consolidate …
ObsEva SA. Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange. GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a …See details»
ObsEva — Sofinnova Partners
ObsEva [NASDAQ: OBSV; SIX: OBSN] is a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. …See details»
ObsEva - Org Chart, Teams, Culture & Jobs - The Org
View ObsEva's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
ObsEva - Contacts, Employees, Board Members, Advisors
Organization. ObsEva . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 10. Number of Board …See details»
ObsEva Announces Update Towards its Strategic Reorganization …
Mar 13, 2023 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a …See details»
ObsEva Announces Update Towards its Strategic Reorganization …
Mar 13, 2023 ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program …See details»
ObsEva Announces Strategic Reorganization to Consolidate
Feb 24, 2023 ObsEva has also notified The Nasdaq Stock Market LLC (“Nasdaq”) of the Company’s inability to comply with Listing Rule 5450(a)(1) because the bid price of ObsEva’s …See details»
ObsEva Announces Corporate Updates - Yahoo Finance
Jul 27, 2022 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a …See details»
ObsEva Announces Corporate Updates - GlobeNewswire
Jul 27, 2022 Risks and uncertainties that may cause actual results to differ materially include uncertainties in the outcome and potential impact of the court-sanctioned moratorium, …See details»
ObsEva Announces Corporate Updates - Yahoo Finance
Jul 27, 2022 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a …See details»